Helicobacter Infections Clinical Trial
Official title:
The Trend of Eradication Rates of First-line Triple Therapy for Helicobacter Pylori and Clinical Factors That Affect the Eradication in Korean: Single Center Experience for Recent Ten Years
The purpose of this study is to investigate the trend of eradication rates of first-line triple therapy for Helicobacter pylori in recent ten years and clinical factors that affect the eradication in Korean.
A PPI triple regimen combining a proton pump inhibitor(PPI) with two antibiotics (amoxicillin and clarithromycin) is currently considered the gold standard therapy for eradication of H. pylori. However, recently the eradication rate with first-line treatment has a tendency to decrease because of increasing antibiotics resistance. In addition, PPI is mainly metabolized by cytochrome p450 2C19 (CYP2C19) in the liver and several reports have suggested that differences in th CYP2C19 genotype are associated with H. pylori eradication failure. Thus, the first aim of this study is to investigate the trend of eradication rates of first-line triple therapy in recent ten years. And the second aim is to analyze the antibiotics resistance rate for H. pylori by using culture minimal inhibitory concentrations(MICs) result and to analyze the association between CYP2C19 genotype and eradication rate of H.pylori. And also investigate the other clinical factors (age, gender, underlying disease, cigarette smoking and alcohol use) that affect the eradication rate. ;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00723502 -
Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients
|
Phase 2 | |
| Recruiting |
NCT03365609 -
A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children
|
N/A | |
| Completed |
NCT00005496 -
Inflammation, Infection, and Future Cardiovascular Risk
|
N/A | |
| Completed |
NCT01219764 -
A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection
|
Phase 4 | |
| Completed |
NCT00216450 -
Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults.
|
Phase 4 | |
| Completed |
NCT00212225 -
Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori)
|
N/A | |
| Completed |
NCT00083291 -
Helicobacter Pylori and Dry Eye
|
N/A | |
| Not yet recruiting |
NCT04652284 -
Effectiveness of Rifabutin for Treatment of Helicobacter Pylori
|
Phase 3 | |
| Completed |
NCT02449941 -
Helicobacter Pylori and Proton Pump Inhibitor
|
N/A | |
| Completed |
NCT02395458 -
Efficacy on Helicobacter Pylori Eradication With Two Antibiotic Regimens
|
Phase 4 | |
| Completed |
NCT00194688 -
Breath Ammonia Method for H. Pylori Detection: Phase II
|
Phase 2 | |
| Not yet recruiting |
NCT02126722 -
Endofaster Test for Helicobacter Pylori Detection in Patients on Proton Pump Inhibitor Therapy
|
N/A | |
| Active, not recruiting |
NCT01133951 -
Helicobacter Pylori Eradication to Prevent Gastric Cancer
|
N/A | |
| Completed |
NCT00669955 -
Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy
|
Phase 3 | |
| Completed |
NCT00816140 -
Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication
|
Phase 4 | |
| Completed |
NCT00490386 -
Helicobacter Pylori and Acute Alcohol Induced Pancreatitis
|
N/A | |
| Withdrawn |
NCT02645201 -
The Effect of Probiotic Combination on Helicobacter Pylori Infection in Children
|
N/A | |
| Terminated |
NCT00664209 -
Treating H. Pylori in Parkinson's Patients With Motor Fluctuations
|
Phase 3 | |
| Completed |
NCT01792700 -
Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy
|
Phase 4 | |
| Completed |
NCT02970110 -
Specimen Collection Study for H. Pylori Testing
|